Loading clinical trials...
Loading clinical trials...
Monotherapy With Piperacillin-tazobactam Versus Combination Therapy With Piperacillin-tazobactam Plus Glycopeptide as an Initial Empiric Therapy for Fever in Neutropenic Patients. An Observational Prospective Study.
Conditions
Interventions
piperacillin-tazobactam
glycopeptide
Locations
12
Spain
A Coruña, Spain
Alcalá de Henares, Spain
Alzira, Spain
Barcelona, Spain
Castellon, Spain
Madrid, Spain
Start Date
July 1, 2001
Primary Completion Date
March 1, 2005
Completion Date
March 1, 2005
Last Updated
November 16, 2009
NCT07388563
NCT00106925
NCT06311227
NCT06285890
NCT05376111
NCT06220162
Lead Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions